Targeting HER2 expression in cancer: New drugs and new indications.
المؤلف | Vranic, Semir |
المؤلف | Gatalica, Zoran |
تاريخ الإتاحة | 2020-06-16T14:25:27Z |
تاريخ النشر | 2020-06-07 |
اسم المنشور | Bosnian Journal of Basic Medical Science |
المعرّف | http://dx.doi.org/10.17305/bjbms.2020.4908 |
الاقتباس | Vranic S, Gatalica Z. Targeting HER2 expression in cancer: New drugs and new indications. Bosn J of Basic Med Sci [Internet]. 2020Jun.7 [cited 2020Jun.16];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/4908 |
الرقم المعياري الدولي للكتاب | 1512-8601 |
الملخص | Functional activation of human epidermal growth factor receptor 2 (HER2) has been shown to strongly promote carcinogenesis, leading to the investigation of HER2-directed agents in cancers with HER2 genomic alterations. This has been best documented in the context of HER2 gene amplification in breast and gastric/gastroesophageal junction carcinomas for which several HER2-directed agents are available and have become a part of standard treatment regimens. Somatic HER2 gene mutations have been recently described at low frequency in a variety of human cancers and have emerged as a novel predictive biomarker for HER2-directed therapies. Preclinical data also indicate that activating HER2 mutations are potent oncogenic drivers in a manner that is analogous to HER2 amplification. HER2 mutations may clinically confer sensitivity to HER2-directed agents as recently shown in a phase II clinical trial with antibody-drug conjugate against HER2 trastuzumab deruxtecan in patients with non-squamous non-small cell lung carcinoma. |
اللغة | en |
الناشر | Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina |
الموضوع | breast cancer lung cancer HER2 mutations treatment |
النوع | Article |
ESSN | 1840-4812 |
الملفات في هذه التسجيلة
هذه التسجيلة تظهر في المجموعات التالية
-
أبحاث الطب [1673 items ]